A01 Antitumor response by T-cell receptor fusion construct (TRuC)-expressing T cells without costimulation. G. Christian Baldeviano. TCR2 Therapeutics, Cambridge, MA.

A02 HER2-specific chimeric antigen receptor T cells with NKILA knockout improve therapeutic effects towards HER2+ breast cancer. Erwei Song. Sun Yat Sen University, Guangzhou, China.


A05 Regulation of CD40L on chimeric antigen receptor T cells enhances immune function translating to antitumor effects. Michelle Fleury. Obsidian Therapeutics, Cambridge, MA.

A06 Sequential two-receptor priming CAR system to overcome heterogeneous antigen expression. Payal B. Watchmaker, University of California San Francisco, San Francisco, CA.

A07 Super2-expressing CAR T cells generate improved antitumor responses to solid tumors. Rachel A. Brog, Dartmouth College, Hanover, NH.

A08 Rationally designed Glypican-2 (GPC2) CAR T-cells effectively eradicate endogenous site density solid tumors in the absence of toxicity. Sabine Heitzeneder. Stanford Cancer Center, Stanford, CA.


A12 Novel DNA-based scaffold promotes rapid T-cell activation, transduction, and high expansion. Anup Sood. Global Research, Niskayuna, NY.

A13 Molecular characterization for CAR-T cell therapy: A step toward standardization with the nCounter® CAR-T Characterization Panel. Christina M. Bailey. NanoString, Seattle, WA.
A14 Phase I adoptive cellular therapy trial with endogenous CD8+ T cells (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers. Apostolia M. Tsimberidou. The University of Texas MD Anderson Cancer Center, Houston, TX.

A15 Repurposing of fenofibrate to prevent and treat PM-induced pulmonary fibroblast-mediated inflammation: Mechanism involved in SIRT1-SREBP1-PIR/NLRP3 inflammasome axis. Chia-Ping Tien. Genomics Research Center, Academia Sinica, Taipei, Taiwan.


A17 Analysis of the impact of VEGF and cannabinoids treatment on prostate cancer cells. Lesetja Raymond Motadi. North-West University, Mmabatho, Republic of South Africa.

A18 Targeting pancreatic cancer using nonengineered, multiantigen-specific T cells (TACTOPS). Brandon G. Smaglo. Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.


A21 Adoptive cell therapy using HER2-specific CD4 T cells for HER2-expressing cancers. Krithika N. Kodumudi. H. Lee Moffitt Cancer Center, Tampa, FL.

A22 Conditioning treatment with a CD27 antibody enhances in vivo expansion and antitumor activity of adoptively transferred T cells. Li-Zhen He. Celldex Therapeutics, Inc., Hampton, NJ.

A23 Adapter CAR T-cells (AdCAR-T) allow precise control on effector function, prevent antigen evasion, and enable differential target cell lysis, based on complex antigen expression profiles. Christian M. Seitz. University Hospital Tuebingen, Tuebingen, Germany.

A24 IL-2 limits CAR T-cell efficacy through selective expansion of a differentiated and less functional subset marked by the loss of CD27 expression. Dongrui Wang. City of Hope, Duarte, CA.

A25 convertibleCAR-T cells provide a highly modular universal system for dose control of activity, targeting flexibility, and in vivo CAR maintenance. Kaman Kim. Xyphos Biosciences, South San Francisco, CA.


A28 Pan-cancer expression analyses identify adenylate kinase modulating immune microenvironment and infiltrating T cell functions in lung cancer that can be overcome by metformin treatment to suppress cancer growth and metastasis. Tsung-Ching Lai. GRC, AS, TPE, Taiwan.
B01 IL-35+ B cells establish immunosuppressive network in pancreatic ductal adenocarcinoma. Bhalchandra Mirlekar, Yuliya Pylayeva-Gupta. The Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.


B05 Targeting the chemokine receptor CCR4 using chimeric antigen receptor T cells for the treatment of CCR4+ T-cell malignancies. Marissa M. Del Real. City of Hope, Duarte, CA.

B07 Optical metabolic imaging and molecular profiling of immune-tumor cell interactions in 3D microfluidic models. Shujah H. Rehman. Morgridge Institute for Research, Madison, WI.


B09 Glioblastoma disguised: Combined therapy using CD19 expressing oncolytic adenovirus and CD19-targeted CAR T cells. Dong Ho Shin, The University of Texas MD Anderson Cancer Center, Houston, TX.

B10 Leveraging the multiparametric profiling by mass cytometry to identify and deeply characterize tumor-reactive T cells. David Roumanes. immunoSCAPE, Inc., Cambridge, MA.

B11 Immunopeptidomics and peptide expression profiles to develop T-cell receptors against glioma-associated antigens. Diego A. Carrera. University of California San Francisco, San Francisco, CA.

B12 Identifying and engineering TCR specificity against mutated self. Martin S. Naradikian. La Jolla Institute for Immunology, San Diego, CA.

B13 Associations of tumor-infiltrating lymphocytes and noncanonical NFκB proteins with the patient outcome. Mithalesh Kumar Singh. Dr. R.P. Centre of Ophthalmic Sciences, ALL India Institute of Medical Sciences, New Delhi, Delhi, India.

B14 Personalized gene editing of T cells to express neoantigen-specific TCRs isolated from peripheral blood of patients on PD-1 blockade therapy. Cristina Puig-Saus. Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine (DGSOM), University of California, Los Angeles (UCLA), Los Angeles, CA.

B16 The effect of CTLA-4 blockade on the expansion of tumor-infiltrating lymphocytes for adoptive cell therapy in metastatic ovarian cancer. Christina Friese. Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, Herlev, Denmark.


B20 Repurposing sildenafil as an immunotherapy agent in lung adenocarcinoma: Mechanism involved in FSTL1-BMP4-Smad-osteopontin axis. Jean Chiou. Academia Sinica, Taipei, Taiwan.

B21 Comparison of NGS-based HLA class I genotyping tools. Jeong-Han Seo. Asan Medical Center, Seoul, Korea.

B22 Common and specific target genes for knockout of MIR 196A1, A2, and B in colon cancer cells. JiSu Mo. Wonkwang University, Iksan, South Korea.

B23 MFN2 modulates thyroid cancer progression through mTORC2/AKT signaling. Mi-Hyeon You. University of Ulsan College of Medicine, Seoul, South Korea.


B25 Predicting CD19Neg relapse following CAR T-cell therapy in B-cell precursor acute lymphoblastic leukemia. Pablo Domizi. Department of Pediatrics, Bass Center for Childhood Cancer and Blood Disorders, Stanford University, Stanford, CA.


B27 RelB upregulates PD-L1 in advanced prostate cancer: An insight into tumor immunoescape. Yanyan Zhang. Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China, 2Nanjing Medical University, Nanjing, China, 3China Pharmaceutical University, Nanjing, China.